Targeting the TGFß pathway with galunisertib, a TGFßRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
J Immunother Cancer
; 6(1): 47, 2018 06 04.
Article
in En
| MEDLINE
| ID: mdl-29866156
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyrazoles
/
Quinolines
/
Transforming Growth Factor beta
/
Combined Modality Therapy
/
Immunotherapy
Type of study:
Prognostic_studies
Limits:
Animals
/
Female
/
Humans
/
Male
Language:
En
Journal:
J Immunother Cancer
Year:
2018
Document type:
Article
Country of publication:
United kingdom